Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized,double-blind,placebo-controlled,crossover trial

Abstract

Introduction

Creatine supplementation has emerged as a promising non-pharmacological therapeutic strategy to counteract muscle dysfunction and low lean mass in a variety of conditions, including in pediatric and rheumatic diseases. The objective of this study was to examine the efficacy and safety of creatine supplementation in childhood systemic lupus erythematosus (C-SLE).

Methods

C-SLE patients with mild disease activity (n = 15) received placebo or creatine supplementation in a randomized fashion using a crossover, double-blind, repeated-measures design. The participants were assessed at baseline and after 12 weeks in each arm, interspersed by an eight-week washout period. The primary outcomes were muscle function, as assessed by a battery of tests including one-maximum repetition (1-RM) tests, the timed-up-and-go test, the timed-stands test, and the handgrip test. Secondary outcomes included body composition, biochemical markers of bone remodeling, aerobic conditioning, quality of life, and physical capacity. Possible differences in dietary intake were assessed by three 24-hour dietary recalls. Muscle phosphorylcreatine content was measured through phosphorus magnetic resonance spectroscopy (31 P-MRS). The safety of the intervention was assessed by laboratory parameters, and kidney function was measured by ⁵¹Cr-EDTA clearance. Additionally, self-reported adverse events were recorded throughout the trial.

Results

Intramuscular phosphorylcreatine content was not significantly different between creatine and placebo before or after the intervention (creatine-Pre: 20.5 ± 2.6, Post: 20.4 ± 4.1, placebo-Pre: 19.8 ± 2.0; Post: 20.2 ± 3.2 mmol/kg wet muscle; p = 0.70 for interaction between conditions). In addition, probably as a consequence of the lack of change in intramuscular phosphorylcreatine content, there were no significant changes between placebo and creatine for any muscle function and aerobic conditioning parameters, lean mass, fat mass, bone mass, and quality of life scores (p > 0.05). The ⁵¹Cr-EDTA clearance was not altered by creatine supplementation and no side effects were noticed.

Conclusion

A 12-week creatine supplementation protocol at 0.1 g/kg/d is well tolerated and free of adverse effects but did not affect intramuscular phosphorylcreatine, muscle function, free-fat mass or quality of life in non-active C-SLE patients.

Trial registration

Clinicaltrials.gov number: NCT01217320.

Keywords

Phosphorylcreatine autoimmune disease muscle metabolism physical capacity

Get full access to this article

View all access options for this article.

References

Watson

Leone

Pilkington

. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64: 2356–2365.

Ravelli

Duarte-Salazar

Buratti

. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis Rheum 2003; 49: 501–507.

Ravelli

Ruperto

Martini

. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17: 568–573.

Lilleby

Haugen

Morkrid

Frey Froslie

Holven

Forre

. Body composition, lipid and lipoprotein levels in childhood-onset systemic lupus erythematosus. Scand J Rheumatol 2007; 36: 40–47.

Alsufyani

Ortiz-Alvarez

Cabral

. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: Relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32: 729–733.

Regio

Bonfá

Takayama

. The influence of lean mass in trabecular and cortical bone in juvenile onset systemic lupus erythematosus. Lupus 2008; 17: 787–792.

Tarnopolsky

Martin

. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52: 854–857.

Gualano B, DE Salles Painneli V, Roschel H, et al. Creatine in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Med Sci Sports Exerc 2011; 43: 770–778.

Neves M Jr, Gualano B, Roschel H, et al. Beneficial effect of creatine supplementation in knee osteoarthritis. Med Sci Sports Exerc 2011; 43: 1538–1543.

10.

Alves

Santiago

Lima

. Creatine supplementation in fibromyalgia: A double-blind, randomized, placebo-controlled trial. Arthritis Care Res (Hoboken) 2013; 65: 1449–1459.

11.

Bourgeois

Nagel

Pearce

Wright

Barr

Tarnopolsky

. Creatine monohydrate attenuates body fat accumulation in children with acute lymphoblastic leukemia during maintenance chemotherapy. Pediatr Blood Cancer 2008; 51: 183–187.

12.

Wyss

Kaddurah-Daouk

. Creatine and creatinine metabolism. Physiol Rev 2000; 80: 1107–1213.

13.

Wallimann

Wyss

Brdiczka

Nicolay

Eppenberger

. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The ‘phosphocreatine circuit’ for cellular energy homeostasis. Biochem J 1992; 281(Pt 1): 21–40.

14.

Wallimann

Tokarska-Schlattner

Schlattner

. The creatine kinase system and pleiotropic effects of creatine. Amino Acids 2011; 40: 1271–1296.

15.

Tarnopolsky

Mahoney

Vajsar

. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 2004; 62: 1771–1777.

16.

Louis

Lebacq

Poortmans

. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27: 604–610.

17.

Kley

Tarnopolsky

Vorgerd

. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2013; 6: CD004760–CD004760.

18.

Gualano

Roschel

Lancha-AH

Brightbill

Rawson

. In sickness and in health: The widespread application of creatine supplementation. Amino Acids 2012; 43: 519–529.

19.

Olsen

Aagaard

Kadi

. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol 2006; 573(Pt 2): 525–534.

20.

Deldicque

Louis

Theisen

. Increased IGF mRNA in human skeletal muscle after creatine supplementation. Med Sci Sports Exerc 2005; 37: 731–736.

21.

Gerber

ap Gwynn

Alini

Wallimann

. Stimulatory effects of creatine on metabolic activity, differentiation and mineralization of primary osteoblast-like cells in monolayer and micromass cell cultures. Eur Cell Mater 2005; 10: 8–22.

22.

Houghton

Tucker

Potts

McKenzie

. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum 2008; 59: 537–545.

23.

Marshall

Tanner

. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 13–23.

24.

Klatchoian

Len

Terreri

. Quality of life of children and adolescents from São Paulo: Reliability and validity of the Brazilian version of the Pediatric Quality of Life Inventory version 4.0 Generic Core Scales. J Pediatr (Rio J) 2008; 84: 308–315.

25.

Brunner

Silverman

Bombardier

Feldman

. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436–444.

26.

Gladman

Ibañez

Urowitz

. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002; 29: 288–291.

27.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

28.

Silva

Avcin

Brunner

. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) 2012; 64: 1787–1793.

29.

Newcomer

Krug

Mahowald

. Validity and reliability of the timed-stands test for patients with rheumatoid arthritis and other chronic diseases. J Rheumatol 1993; 20: 21–27.

30.

Podsiadlo

Richardson

. The timed “Up & Go”: A test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142–148.

31.

Prado

Benatti

de Sá-Pinto

. Exercise training in childhood-onset systemic lupus erythematosus: A controlled randomized trial. Arthritis Res Ther 2013; 15: R46–R46.

32.

Pecoraro

Guida

Caroli

. Body mass index and skinfold thickness versus bioimpedance analysis: Fat mass prediction in children. Acta Diabetol 2003; 40(Suppl 1): S278–S281.

33.

Carter

Bouxsein

Marcus

. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137–145.

34.

Santiago

Silva

Caparbo

Sallum

Pereira

. Bone mineral apparent density in juvenile dermatomyositis: The role of lean body mass and glucocorticoid use. Scand J Rheumatol 2008; 37: 40–47.

35.

Baim

Wilson

Lewiecki

Luckey

Downs

RW Lentle

. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: Position paper of the International Society for Clinical Densitometry. J Clin Densitom 2005; 8: 371–378.

36.

Lopes

Danilevicius

Takayama

. Prevalence and risk factors of radiographic vertebral fracture in Brazilian community-dwelling elderly. Osteoporos Int 2011; 22: 711–719.

37.

Machado

Ruperto

Silva

. The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19(4 Suppl 23): S25–S29.

38.

Gualano

de Salles Painelli

Roschel

. Creatine supplementation does not impair kidney function in type 2 diabetic patients: A randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol 2010; 111: 749–756.

39.

Tarnopolsky

Mahoney

Thompson

Naylor

Doherty

. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1. Muscle Nerve 2004; 29: 51–58.

40.

Deldicque

Theisen

Bertrand

Hespel

Hue

Francaux

. Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways. Am J Physiol Cell Physiol 2007; 293: C1263–C1271.

41.

Hultman

Söderlund

Timmons

Cederblad

Greenhaff

. Muscle creatine loading in men. J Appl Physiol (1985) 1996; 81: 232–237.

42.

Rawson

Clarkson

Price

Miles

. Differential response of muscle phosphocreatine to creatine supplementation in young and old subjects. Acta Physiol Scand 2002; 174: 57–65.

43.

Zange J, Kornblum C, Müller K, et al. Creatine supplementation results in elevated phosphocreatine/adenosine triphosphate (ATP) ratios in the calf muscle of athletes but not in patients with myopathies. Ann Neurol 2002; 52: 126; author reply 126–127.

44.

Tarnopolsky

Parise

. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999; 22: 1228–1233.

45.

Fitch

Moody

. Creatine metabolism in skeletal muscle. V. An intracellular abnormality of creatine trapping in dystrophic muscle. Proc Soc Exp Biol Med 1969; 132: 219–222.

46.

Lugaresi

Leme

de Salles Painelli

. Does long-term creatine supplementation impair kidney function in resistance-trained individuals consuming a high-protein diet? J Int Soc Sports Nutr 2013; 10: 26–26.

47.

Gualano

Ugrinowitsch

Novaes

. Effects of creatine supplementation on renal function: A randomized, double-blind, placebo-controlled clinical trial. Eur J Appl Physiol 2008; 103: 33–40.

48.

Gualano

Ferreira

Sapienza

Seguro

Lancha

AH . Effect of short-term, high-dose creatine supplementation on measured GFR in a young man with a single kidney. Am J Kidney Dis 2010; 55: e7–e9.

49.

Tarnopolsky

Parise

. Acute and moderate-term creatine monohydrate supplementation does not affect creatine transporter mRNA or protein content in either young or elderly humans. Mol Cell Biochem 2003; 244: 159–166.

50.

Vorgerd

Zange

Kley

. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: Double-blind, placebo-controlled crossover study. Arch Neurol 2002; 59: 97–101.